The Global Health Body Raises Warning Over Acute Shortage of Weight-Loss Jabs
Fewer than one in 10 people that would benefit from weight-loss injections like Wegovy have access to them, warns the global health agency as it publishes its inaugural guidance on the therapies.
With over a billion people worldwide now living with obesity, it is urging more widespread and fairer availability to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidance acknowledges that obesity is a lifelong illness that can be treated with holistic and ongoing treatment," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major obstacles to widespread access to the jabs that can aid individuals in losing considerable body mass, notes the agency.
Weight-Loss Drug Scarcity
Even under the present most optimistic case, the production of such drugs could only cover around 100 million people – less than 10% of eligible patients, according to the health organization.
The recommendation urges nations and manufacturers to widen availability, via measures like voluntary licensing.
The intellectual property rights on the active ingredient – the primary ingredient of a leading brand – is due to expire in a number of nations in 2026.
How Obesity Jabs Operate
GLP-1 drugs mimick a biological compound to delay gastric emptying, reduce hunger and boost feelings of fullness so people reduce food intake.
People typically see weight reduction after several weeks of commencing the regular doses.
Research suggests users may put most of the weight back on after a year of discontinuing the treatment, because their normal hunger come back.
Being overweight or obese raises your chance for developing diseases, including type 2 diabetes, heart disease, stroke, and specific cancers.
Excess weight affects people in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.
